1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

 
• By Emily Hayes

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

T-cells attacking cancer_1200x675

The combination of Nektar Therapeutics' investigational interleukin-2 (IL-2) agent NKTR-214 with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo has activity in lung, kidney cancer and melanoma, the partners said at the Society for Immunotherapy and Cancer meeting in November.

Nektar and Bristol presented positive early data for the combination of NKTR-214 and Opdivo in renal cell carcinoma, melanoma and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.